Iron sucrose

Generic Name
Iron sucrose
Brand Names
Velphoro, Venofer
Drug Type
Small Molecule
Chemical Formula
C12H29Fe5Na2O23
CAS Number
8047-67-4
Unique Ingredient Identifier
FZ7NYF5N8L
Background

Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic ...

Indication

Iron sucrose is elemental iron as an injection. It replenishes body iron stores in patients with iron deficiency.

Associated Conditions
Hyperphosphataemia
Associated Therapies
-
Clinical Trials
Related News

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

Phase 2
Recruiting
Conditions
Anemia
Interventions
Drug: Venofer
First Posted Date
2023-04-05
Last Posted Date
2023-08-24
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
34
Registration Number
NCT05800600
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Bioequivalence Study Comparing Single Dose of Ferrinemia® Injection With a Single Dose of Venofer® Injection in Healthy Male Volunteers

Phase 1
Completed
Conditions
Heathy Volunteers
Interventions
Drug: Venofer
Drug: Ferrinemia
First Posted Date
2017-03-28
Last Posted Date
2018-07-05
Lead Sponsor
Azad Pharma AG
Target Recruit Count
48
Registration Number
NCT03093883
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia

First Posted Date
2016-04-07
Last Posted Date
2018-03-06
Lead Sponsor
Zeria Pharmaceutical
Target Recruit Count
238
Registration Number
NCT02731534

Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)

Completed
Conditions
Hyperphosphatemia
Interventions
Drug: sucroferric oxyhydroxide
First Posted Date
2016-02-22
Last Posted Date
2019-10-01
Lead Sponsor
Vifor Fresenius Medical Care Renal Pharma
Target Recruit Count
1400
Registration Number
NCT02687594
Locations
🇫🇷

Centre Hospitalier LYON-SUD, Pierre Benite, France

🇩🇪

Klinikum Coburg, Coburg, Germany

🇬🇧

Salford Royal Hospitals NHS Trust, Manchester, United Kingdom

and more 4 locations

The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron

First Posted Date
2015-03-18
Last Posted Date
2017-04-12
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
40
Registration Number
NCT02390921
Locations
🇪🇸

Hospital Universitari Vall d'Hebron, Barcelona, Spain

Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients

Phase 2
Completed
Conditions
Anemia
Interventions
Drug: Venofer
First Posted Date
2008-07-23
Last Posted Date
2018-02-20
Lead Sponsor
American Regent, Inc.
Target Recruit Count
11
Registration Number
NCT00721188
Locations
🇺🇸

Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States

Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia

Phase 3
Completed
Conditions
Anemia
Interventions
Drug: Ferrous Sulfate
Drug: Venofer
First Posted Date
2005-10-12
Last Posted Date
2020-10-06
Lead Sponsor
American Regent, Inc.
Target Recruit Count
182
Registration Number
NCT00236977
Locations
🇺🇸

Luitpold Pharmaceuticals, Valley Forge, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy